Zudena (udenafil) is a phosphodiesterase type 5 (PDE5) inhibitor specifically developed for the management of erectile dysfunction (ED). As a selective and potent agent, it offers a reliable therapeutic option with a favorable pharmacokinetic profile, including rapid onset and sustained duration of action. Its mechanism targets the underlying physiological pathways involved in achieving and maintaining erection, providing a clinically validated solution for men experiencing ED. This product card provides comprehensive, evidence-based information for healthcare professionals and informed patients.

Features

• Active ingredient: Udenafil 100 mg
• Pharmacological class: Phosphodiesterase type 5 (PDE5) inhibitor
• Onset of action: As early as 30 minutes post-administration
• Duration of effect: Up to 12 hours
• Administration: Oral tablet
• Manufacturer compliance: GMP-certified production

Benefits

• Facilitates improved erectile function through selective PDE5 inhibition
• Offers extended therapeutic window allowing for spontaneity
• Demonstrates high selectivity reducing off-target effects
• Supported by clinical trials showing significant efficacy versus placebo
• Suitable for a broad range of ED etiologies
• Well-tolerated profile with manageable side effects

Common use

Zudena is indicated for the treatment of erectile dysfunction in adult males. It is used to enhance erectile function only in the presence of sexual stimulation. It is not indicated for use in women, children, or adolescents. Clinical use is supported by diagnostic confirmation of ED, and it may be prescribed for both psychogenic and organic causes, including cases associated with diabetes mellitus, hypertension, or post-prostatectomy scenarios, following a thorough medical evaluation.

Dosage and direction

The recommended dose is 100 mg taken orally approximately 30 to 60 minutes before anticipated sexual activity. Administration with or without food is acceptable, though high-fat meals may delay time to peak concentration. Dose adjustment to 50 mg may be considered based on individual efficacy and tolerability, particularly in elderly patients or those with hepatic impairment. Do not exceed one dose within a 24-hour period. The tablet should be swallowed whole with a glass of water.

Precautions

Prior to prescribing or using Zudena, cardiovascular status should be assessed due to the mild systemic vasodilatory effects. It is not intended for use in men for whom sexual activity is inadvisable due to underlying cardiovascular pathology. Use with caution in patients with anatomical deformation of the penis, history of priapism, bleeding disorders, or active peptic ulceration. Avoid concurrent consumption of grapefruit juice, which may increase plasma concentrations. Renal or hepatic impairment necessitates careful dose consideration.

Contraindications

Zudena is contraindicated in patients with a known hypersensitivity to udenafil or any excipients in the formulation. Concurrent use with organic nitrates or nitric oxide donors in any form is absolutely contraindicated due to the risk of profound hypotension. It is also contraindicated in patients with severe hepatic impairment, end-stage renal disease requiring dialysis, hereditary degenerative retinal disorders, or a history of non-arteritic anterior ischemic optic neuropathy (NAION).

Possible side effects

The most commonly reported adverse reactions are headache, flushing, nasal congestion, dyspepsia, and dizziness. These are generally mild to moderate in intensity and transient. Less frequently, visual disturbances (such as altered color perception), myalgia, and back pain have been reported. Priapism (a prolonged and painful erection lasting more than 4 hours) is a rare but serious adverse event requiring immediate medical intervention to prevent permanent tissue damage.

Drug interaction

Concomitant use with nitrates is contraindicated. Potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, erythromycin) may significantly increase udenafil exposure—dose reduction should be considered. Alpha-blockers may potentiate the blood-pressure-lowering effects. Use with other antihypertensives may cause additive hypotensive effects. Zudena may potentiate the hypotensive effects of alcohol.

Missed dose

Zudena is not intended for chronic daily dosing and is taken on an as-needed basis. A missed dose is not applicable. Do not take an extra dose to make up for a missed opportunity. The next dose should be taken at the next intended sexual activity, adhering to the minimum 24-hour interval between doses.

Overdose

In cases of suspected overdose, standard supportive measures should be employed. Expected effects would be an extension of the drug’s vasodilatory properties, potentially leading to severe hypotension, syncope, or prolonged erection. Management of hypotension may require fluid resuscitation and appropriate positioning. Priapism requires urgent urological consultation. Hemodialysis is not expected to significantly enhance elimination due to high protein binding and extensive tissue distribution.

Storage

Store at room temperature (15–30°C or 59–86°F) in the original packaging to protect from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Do not flush medications down the toilet or pour them into a drain unless instructed to do so.

Disclaimer

This information is intended for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here.

Reviews

“In my clinical practice, udenafil has provided a valuable option within the PDE5 inhibitor class. Its duration of action is particularly appreciated by patients seeking flexibility.” – Dr. A. Sharma, Urologist “Effective and well-tolerated. The side effect profile appears manageable for most of my patients with comorbid conditions.” – Dr. L. Chen, Andrologist “Studies demonstrate a consistent efficacy rate and a rapid onset, making it a competitive choice in the therapeutic landscape for erectile dysfunction.” – Clinical Pharmacologist Review